查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363049

遗传性血管水肿治疗药物市场规模、份额和趋势分析报告：2023-2030 年按治疗、给药途径、最终用途、地区和细分市场分類的趋势

Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report By Treatment (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor), By Route of Administration, By End Use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

遗传性血管水肿治疗药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球遗传性血管水肿治疗市场规模将达58亿美元，2023年至2030年年复合成长率为7.4%。

国际患者组织为提高患者和医疗保健提供者对遗传性血管性水肿 (HAE) 的认识而采取的倡议可能会成为市场的有力促进因素。

隶属于 HAE International (HAEi) 的病患权益团体致力于透过印刷品和社群媒体进行宣传活动，以提高人们对遗传性血管性水肿的认识。 HAEi 也推出了居家检测工具来提高患者的意识层级，这将有助于提供准确的诊断和最佳的医疗照护。 CSL Limited、Pharming Group NV 和 Shire Plc. 等製药和生物技术公司也参与开发 HAE治疗方法，并与遗传性血管水肿界合作，致力于建立有效的遗传性血管水肿诊断流程和治疗方法。

世界不同国家的大学正在相互合作开发新的治疗方法来控制遗传性血管水肿的发作。例如，2018 年，来自欧洲、澳洲和加拿大的 26 所大学开展了一项国际合作，开发预防这种疾病的新型口腔疗法。

各国正在采取措施改善患者获得新治疗方法的机会，并修订法规指南以促进 HAE 药物的快速审查和核准，预计将有助于市场成长。例如，2018年7月，中国国家卫生健康委员会（NHC）和国家药品监督（SDA）宣布，药品生产商可以申请新药认证，用于治疗方法目前国内尚无治疗方法的罕见疾病。（保密协议）。该决定允许药品生产企业在申请新药认证时使用中国境外的临床试验资料。

遗传性血管水肿治疗药物市场报告亮点

  • 由于产品在 HAE 的按需和预防性治疗中的高利用率，C1 酯酶抑制剂细分市场在 2022 年占据最大份额。
  • 按需治疗占据了市场的压倒性份额，预计在预测期内将出现良好的成长。新地区的产品推出预计将成为该细分市场的主要促进因素。
  • 以 2022 年销售额计算，北美在整个遗传性血管水肿治疗药物市场中占据主导地位。这种疾病病例数量的增加、有利的政府计划、患者意识水平的提高以及高度专业化的医疗保健专业人员的存在是促成该区域市场主要份额的要素。
  • 由于医疗基础设施的改善和未满足的医疗需求较高，预计亚太地区在预测期内将出现良好的成长。此外，治疗这种疾病的新治疗方法的推出可能会推动该地区的市场成长。
  • 主要参与者包括 Ionis Pharmaceuticals, Inc.、BioCryst Pharmaceuticals, Inc.、Pharming Group NV、CSL Limited、Shire plc、Adverum Biotechnologies, Inc.、Attune Pharmaceuticals, Inc.、KalVista Pharmaceuticals, Inc.。

目录

第1章调查方法和范围

第2章执行摘要

第3章遗传性血管水肿治疗药物市场变数、趋势与范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 遗传性血管水肿治疗药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章遗传性血管水肿治疗药物市场：依治疗方法估计与趋势分析

  • 遗传性血管水肿治疗市场：重点
  • 遗传性血管水肿治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • C1-酯酶抑制剂
  • 缓激肽 B2 受体拮抗
  • 激肽释放酶抑制剂
  • 其他的

第5章遗传性血管水肿治疗药物市场：依最终用途的估计与趋势分析

  • 遗传性血管水肿治疗市场：重点
  • 遗传性血管水肿治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 预防
  • 按需

第6章遗传性血管水肿治疗药物市场：依给药途径估计与趋势分析

  • 遗传性血管水肿治疗市场：重点
  • 遗传性血管水肿治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 静脉
  • 皮下的
  • 口服

第7章遗传性血管水肿治疗药物市场：区域估计与趋势分析

  • 区域展望
  • 按地区分類的遗传性血管水肿治疗药物市场：重点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第8章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • BioCryst Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals
    • CSL
    • Attune Pharmaceuticals
    • Adverum Biotechnologies, Inc.
    • KalVista Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Pharming
Product Code: GVR-3-68038-156-6

Hereditary Angioedema Therapeutics Market Growth & Trends:

The global hereditary angioedema therapeutic market size is expected to reach USD 5.8 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a 7.4% CAGR from 2023 to 2030. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.

Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the hereditary angioedema community so as to create effective diagnosis process and treatment for the condition.

Universities in different countries across the globe are collaborating with each other in order to develop new therapies for the management of hereditary angioedema attacks. For instance, in 2018, 26 universities from Europe, Australia, and Canada collaborated on an international study to develop a novel oral therapy for prevention of the condition.

Measures undertaken by countries for improving patient access to new therapies, along with modification in regulatory guidelines for facilitating faster drug review and approval for HAE, are expected to contribute to market growth. For instance, in July 2018, China's National Health Commission (NHC) and State Drug Administration (SDA) allowed pharmaceutical drug manufacturers to file for New Drug Application (NDA) for therapies for rare diseases whose treatment is currently not available in the country. The decision has allowed drug manufacturers to use clinical trial data from outside China while filing for NDA.

Hereditary Angioedema Therapeutics Market Report Highlights:

  • The C1-esterase inhibitor segment held the largest share in 2022 owing to high usage rates of the products in on-demand and prophylactic treatment of HAE
  • On-demand treatment accounted for the dominant share in the market and is expected to witness lucrative growth over the forecast period. Expected launch of products in new geographies is likely to be a key growth driver for the segment
  • North America dominated the overall hereditary angioedema therapeutics market in terms of revenue in 2022. Growing number of cases of the condition, favorable government programs, increasing awareness levels among patients, and presence of highly expert healthcare professionals are factors contributing to the major share of this regional market
  • Asia Pacific is expected to register lucrative growth over the forecast period owing to improving healthcare infrastructure and high unmet medical needs. Moreover, launch of new therapies for the treatment of the condition is likely to facilitate market growth in the region
  • Key players include Ionis Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; Pharming Group N.V.; CSL Limited; Shire plc; Adverum Biotechnologies, Inc.; Attune Pharmaceuticals, Inc.; and KalVista Pharmaceuticals, Inc.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment
    • 1.1.2. End-use
    • 1.1.3. Route of administration
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Route of administration outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hereditary Angioedema Therapeutic Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Hereditary Angioedema Therapeutic Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Hereditary Angioedema Therapeutic Market: Treatment Estimates & Trend Analysis

  • 4.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 4.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. C1-esterase Inhibitor
    • 4.3.1. C1-esterase inhibitor market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.4. Bradykinin B2 Receptor Antagonist
    • 4.4.1. Bradykinin B2 receptor antagonist market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.5. Kallikrein Inhibitor
    • 4.5.1. Kallikrein inhibitor market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Hereditary Angioedema Therapeutic Market: End-use Estimates & Trend Analysis

  • 5.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 5.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Prophylaxis
    • 5.3.1. Silicon market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.4. On-demand
    • 5.4.1. Metal market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 6. Hereditary Angioedema Therapeutic Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 6.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Intravenous
    • 6.3.1. Intravenous market estimates and forecasts, 2018 to 2030, (USD Million)
  • 6.4. Subcutaneous
    • 6.4.1. Subcutaneous market estimates and forecasts, 2018 to 2030, (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 7. Hereditary Angioedema Therapeutic Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Hereditary Angioedema Therapeutic Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. BioCryst Pharmaceuticals, Inc.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Ionis Pharmaceuticals
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. CSL
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Attune Pharmaceuticals
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Adverum Biotechnologies, Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. KalVista Pharmaceuticals, Inc.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Takeda Pharmaceutical Company Limited
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Pharming
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiative

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 3 North America hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 North America hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 7 U.S. hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 Canada hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Canada hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12 Europe hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Europe hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Europe hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Germany hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Germany hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 UK hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 UK hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 21 UK hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 France hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 France hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 France hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 25 Italy hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Italy hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Italy hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 Spain hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Spain hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Spain hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 - 2030
  • Table 31 Denmark hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Denmark hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 Denmark hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 34 Sweden hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 35 Sweden hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 36 Sweden hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Norway hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Norway hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 Norway hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Japan hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 45 Japan hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Japan hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 - 2030
  • Table 47 China hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 China hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 49 China hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 50 India hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 India hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 India hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 -2030
  • Table 53 Australia hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 Australia hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 55 Australia hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 -2030
  • Table 56 Thailand hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 57 Thailand hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 58 Thailand hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 South Korea hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 South Korea hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 South Korea hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 62 Latin America hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 Latin America hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 64 Latin America hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65 Latin America hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 66 Brazil hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 67 Brazil hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 68 Brazil hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 Mexico hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 70 Mexico hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 Mexico hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 Argentina hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 73 Argentina hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 74 Argentina hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 80 South Africa hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 81 South Africa hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 UAE hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 86 UAE hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 87 UAE hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 Kuwait hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 89 Kuwait hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 90 Kuwait hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Hereditary angioedema therapeutics: Market outlook
  • Fig. 9 Hereditary angioedema therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Hereditary angioedema therapeutics market driver impact
  • Fig. 15 Hereditary angioedema therapeutics market restraint impact
  • Fig. 16 Hereditary angioedema therapeutics market strategic initiatives analysis
  • Fig. 17 Hereditary angioedema therapeutics market: Treatment movement analysis
  • Fig. 18 Hereditary angioedema therapeutics market: Treatment outlook and key takeaways
  • Fig. 19 C1-esterase inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Bradykinin B2 receptor antagonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Kallikrein inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Hereditary angioedema therapeutics market: End-use movement analysis
  • Fig. 24 Hereditary angioedema therapeutics market: End-use outlook and key takeaways
  • Fig. 25 Prophylaxis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 On-demand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Hereditary angioedema therapeutics market: Route of administration movement analysis
  • Fig. 28 Hereditary angioedema therapeutics market: Route of administration outlook and key takeaways
  • Fig. 29 Intravenous market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Subcutaneous market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Global hereditary angioedema therapeutics market: Regional movement analysis
  • Fig. 33 Global hereditary angioedema therapeutics market: Regional outlook and key takeaways
  • Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)